Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 7/12/22 → 4/27/25 |
Funding
- Gilead Sciences Inc: $36,699.00
22-MULTI-47-GS (IMMU-132-11): A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors
- Arnold, Susanne (PI)